Last reviewed · How we verify
NCT03932071
Zoledronic Acid in Decrease the Lung Metastatic Rate of Osteosarcoma
Phase 4 trial testing Zoledronic Acid in Lung Metastases in 150 participants. Status unknown.
1 January 2020
Quick facts
| Lead sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 150 |
| Start date | 1 January 2017 |
| Primary completion | 1 January 2020 |
| Estimated completion | 1 January 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Zoledronic Acid (ZOLEDRONIC ACID) — full drug profile →
Conditions studied
- Lung Metastases — all drugs for Lung Metastases →
- Tumor Necrosis — all drugs for Tumor Necrosis →
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Who can join
Eligibility, any sex, with Lung Metastases or Tumor Necrosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Zoledronic acid is an adjuvant treatment for primary osteosarcoma. Zoledronic acid has been widely used in the treatment of metastatic bone tumors. In addition to its inhibition of tumor osteoclasis, it also produces certain killing of tumor cells. effect. Foreign studies have shown that zoledronic acid also has a killing effect on osteosarcoma and has a certain inhibitory effect on distant metastasis. We hope that it can reduce tumor recurrence and lung metastasis through this study.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Recent and Ongoing Research into Metastatic Osteosarcoma Treatments.
Harris MA, Hawkins CJ. · · 2022 · cited 100× · PMID 35409176 · DOI 10.3390/ijms23073817 -
Pathogenesis and Current Treatment of Osteosarcoma: Perspectives for Future Therapies.
Rathore R, Van Tine BA. · · 2021 · cited 81× · PMID 33809018 · DOI 10.3390/jcm10061182 -
Inhibiting Endothelin Receptors with Macitentan Strengthens the Bone Protective Action of RANKL Inhibition and Reduces Metastatic Dissemination in Osteosarcoma.
Muñoz-Garcia J, Vargas-Franco JW, Royer BB, Cochonneau D, et al · · 2022 · cited 4× · PMID 35406536 · DOI 10.3390/cancers14071765
Verify or expand the search:
- PubMed search for NCT03932071
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Zoledronic Acid
Trials testing the same drug.
- NCT05666310 — Muscle Impact of Treating Osteoporosis · Phase 4 · active not recruiting
- NCT04597931 — Evaluation of Romosozumab vs. Zoledronic Acid Effect in Patients With Spinal Cord Injury and Low Bone Mineral Density · Phase 4 · unknown
- NCT04736693 — Replication of the HORIZON Pivotal Fracture Trial in Healthcare Claims Data · completed
- NCT04087096 — Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery · Phase 4 · completed
- NCT04303026 — The Effect of Zoledronic Acid on Patients With Osteoarthritis of the Hip · Phase 3 · unknown
Other recruiting trials for Lung Metastases
Currently open trials in the same condition.
- NCT07112989 — Development of Innovative Preclinical Ex Vivo Models for the Study of Sarcomas and Metastases From Solid Tumors · recruiting
- NCT05611034 — In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung · Phase 1 · recruiting
- NCT04940936 — Shared Decision Making on Radiation Dose for Lung Malignancies · NA · recruiting
- NCT05375591 — AI & Radiomics for Stratification of Lung Nodules After Radically Treated Cancer · recruiting
- NCT04684186 — Comparison Between Endovascular and Bronchoscopic Tumor Marker Insertion for Real-time Stereotactic-guided Radiotherapy · recruiting
Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials
Trials by the same sponsor.
- NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
- NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
- NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
- NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
- NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03932071 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
- Last refreshed: 6 May 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03932071.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing